Benitec Biopharma Inc. BNTC
We take great care to ensure that the data presented and summarized in this overview for Benitec Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BNTC
Top Purchases
Top Sells
About BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Insider Transactions at BNTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 31
2025
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
16,497
+0.09%
|
$197,964
$12.93 P/Share
|
|
Mar 26
2025
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
900,000
+8.67%
|
$11,700,000
$13.0 P/Share
|
|
Mar 12
2025
|
J Kevin Buchi Director |
BUY
Bona fide gift
|
Indirect |
103,626
+50.0%
|
-
|
|
Mar 12
2025
|
J Kevin Buchi Director |
SELL
Bona fide gift
|
Direct |
103,626
-99.73%
|
-
|
|
Feb 27
2025
|
J Kevin Buchi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
51,813
+33.27%
|
$155,439
$3.86 P/Share
|
|
Dec 24
2024
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
20,018
+0.23%
|
$220,198
$11.25 P/Share
|
|
Dec 23
2024
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
27,502
+0.32%
|
$275,020
$10.98 P/Share
|
|
Dec 03
2024
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
42,000
+0.48%
|
$378,000
$9.6 P/Share
|
|
Nov 20
2024
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
27,436
+0.31%
|
$274,360
$10.22 P/Share
|
|
Nov 19
2024
|
Suvretta Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
14,000
+0.16%
|
$126,000
$9.73 P/Share
|
|
Sep 26
2024
|
Suvretta Capital Management, LLC |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,137,763
+26.4%
|
$7,137,763
$1.93 P/Share
|
|
Aug 11
2023
|
J Kevin Buchi Director |
BUY
Open market or private purchase
|
Direct |
51,813
+49.86%
|
-
|
|
Aug 11
2023
|
Megan Boston Executive Director |
BUY
Open market or private purchase
|
Direct |
25,907
+50.0%
|
-
|
|
Dec 09
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,553
+1.04%
|
$31,659
$3.04 P/Share
|
|
Nov 29
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,947
+3.69%
|
$113,841
$3.18 P/Share
|
|
May 03
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,500
+4.08%
|
$162,000
$4.25 P/Share
|
|
Apr 30
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
120,000
+11.64%
|
$480,000
$4.18 P/Share
|
|
Apr 29
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,877
+2.81%
|
$114,385
$5.49 P/Share
|
|
Apr 28
2021
|
Steven Michael Oliveira > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+11.52%
|
$500,000
$5.45 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.05M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 7.14M shares |
| Bona fide gift | 104K shares |
| Exercise of conversion of derivative security | 51.8K shares |
| Bona fide gift | 104K shares |
|---|